Literature DB >> 3131053

Interleukin-2 receptor expression in peripheral blood lymphocytes from systemic lupus erythematosus patients: relationship to clinical activity.

D R Wigfall1, R S Sakai, D J Wallace, S C Jordan.   

Abstract

Deficient interleukin-2 (IL-2) production and other T-cell dysfunctions have been demonstrated in active systemic lupus erythematosus (SLE). The generation of IL-2 receptors is known to be important to the growth and differentiation of T and B lymphocytes. This study investigated IL-2 receptor expression in peripheral blood lymphocytes (PBL) from patients with active and inactive SLE. PBL from 27 SLE patients, diagnosed by revised ARA criteria, were assayed for IL-2 receptor expression, IL-2 and immunoglobulin (Ig) production. PBL from SLE patients with active disease spontaneously expressed increased numbers of IL-2 receptors compared to those with inactive disease (P less than 0.01) and normal donors (P less than 0.01). There was no significant increase in IL-2 receptors expression in PBL from active SLE patients in response to mitogenic stimulation with PHA compared to inactive SLE patients and normal donors. There was negligible IL-2 production in response to mitogenic stimulation and increased spontaneous IgG production by PBL from active SLE patients compared to normal donors (P less than 0.001). Purified B cells isolated from active SLE patients showed significant spontaneous IL-2 receptor expression when compared to spontaneous IL-2 receptor expression by normal B cells (P = 0.005). Therefore, in addition to derangements in Ig and IL-2 production, the level of spontaneous expression of IL-2 receptors may represent a cellular indicator of disease activity, and hence, may be a useful parameter in monitoring disease activity in SLE patients. The significance of the increased IL-2 receptor expression on B cells of active SLE patients is unknown, but may represent a marker of polyclonal activation of these cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3131053     DOI: 10.1016/s0090-1229(88)80012-6

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  10 in total

Review 1.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Expression of IL-2R, IL-4R, IL-6R on peripheral blood lymphocytes in systemic lupus erythematosus and correlation with disease activity: a prospective study.

Authors:  E Y Chan; C S Lau; H Zola
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

3.  Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus.

Authors:  K Abe; Y Takasaki; C Ushiyama; J Asakawa; T Fukazawa; M Seki; M Hirashima; M Ogaki; H Hashimoto
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.317

4.  Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus.

Authors:  E J ter Borg; G Horst; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

5.  cAMP-responsive element modulator (CREM)α protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus.

Authors:  Christian M Hedrich; Thomas Rauen; George C Tsokos
Journal:  J Biol Chem       Date:  2011-10-05       Impact factor: 5.157

6.  Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.

Authors:  K L Lim; A C Jones; N S Brown; R J Powell
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

7.  The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity.

Authors:  Linda A Lieberman; George C Tsokos
Journal:  J Biomed Biotechnol       Date:  2010-06-06

8.  Serum soluble interleukin 2 receptor in systemic lupus erythematosus: effects of disease activity and infection.

Authors:  K L Wong; R P Wong
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

9.  Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia.

Authors:  Y Amasaki; S Kobayashi; T Takeda; N Ogura; S Jodo; T Nakabayashi; A Tsutsumi; A Fujisaku; T Koike
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

10.  Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis.

Authors:  Enken Gundlach; Michael Marcus Hoffmann; Antje Prasse; Sonja Heinzelmann; Thomas Ness
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.